Background: Chordoid glioma of the third ventricle is a rare neuroepithelial tumor characterized by a unique histomorphology within the third ventricular region, but with radiological and histopathological features mimicking benign lesions such as meningioma. We report a case of chordoid glioma of the third ventricle and suggest a useful indicator for accurate diagnosis. Case Description: A previously healthy 46-year-old woman was admitted to our hospital with mild headache. Neuroimaging revealed a large tumor measuring approximately 18 mm in the suprasellar region, and perifocal edema in the optic tract and internal capsule on magnetic resonance imaging. Laboratory findings revealed no pituitary dysfunction including diabetes insipidus. Gross total resection of the tumor was performed by the interhemispheric translamina terminalis approach. Histological findings revealed nests of regular epithelioid cells with large nuclei and abundant eosinophilic cytoplasm within myxoid stroma. Immunohistochemical studies demonstrated diffuse cytoplasmic expression of glial fibrillary acidic protein (GFAP) and CD34, and strong nuclear staining for thyroid transcription factor 1 (TTF-1). We, therefore, histologically classified the tumor as chordoid glioma of the third ventricle. Headache improved immediately postoperatively, and follow-up neuroimaging after 12 months showed no signs of recurrence. Conclusions: Chordoid glioma of the third ventricle is a very rare tumor that is difficult to diagnose on routine neuroimaging. Accurate diagnosis requires detailed
INTRODUCTION
Chordoid glioma of the third ventricle is a rare, slow-growing, noninvasive glial tumor in the third ventricle with uncertain histogenesis and chordoid appearance, first described as a clinicopathologic entity by Brat and colleagues in 1998. [3] This tumor was initially considered a variant of meningioma, but was subsequently accepted as a distinct glioma and classified as grade II according to the 2016 World Health Organization (WHO) classification of brain tumors. [2, 3, 9, [12] [13] [14] 19, 20] Due to its rarity, the definitive features of the clinical course, treatment strategy, and prognosis have not been elucidated. [3, 8, 13] Therefore, it is necessary for recognizing the characteristic features of this tumor, including neuroimaging, pathological findings, and risks of surgical procedures. Here, we report a case of chordoid glioma of the third ventricle, and suggest both useful indicators for accurate diagnosis using findings from neuroimaging and pathological examinations, and pitfalls for the treatment strategy.
CASE DESCRIPTION
A previously healthy 46-year-old woman presented to our department with a 6-month history of mild headache. Intracranial computed tomography (CT) revealed an iso-dense mass without calcification in the anterior area of the third ventricle. Magnetic resonance imaging (MRI) demonstrated that the tumor (diameter, 14 × 18 × 18 mm) was predominantly isointense on T1-weighted imaging (T1WI) and T2-weighted imaging (T2WI), and homogeneously enhanced to a high degree with gadolinium (Gd) [ Figure 1 ]. The optic chiasma was displaced downwards, and the anterior wall of the third ventricle was deviated. Perilesional edema reaching up to the mesencephalon bilaterally and the internal capsule associated with compression by the tumor mass were clearly observable on fluid-attenuated inversion recovery (FLAIR) MRI [ Figure 2 ]. No pituitary insufficiency was evident from laboratory examinations. Preoperative differential diagnoses included intraventricular meningioma, craniopharyngioma, ependymoma, and chordoid glioma of the third ventricle. To confirm the histological diagnosis, the tumor was resected microsurgically under an interhemispheric translamina terminalis approach to the third ventricle.
Intraoperative examination demonstrated that the tumor was firm, rubbery, and nonsuckable, and appeared to be originating from the lamina terminalis with a clear margin between normal structures including the hypothalamus. We achieved gross total resection of the tumor to reduce compression of the optic nerve. Histopathological examination with hematoxylin and eosin (HE) staining of the tumor showed a neoplastic tissue comprising eosinophilic epithelioid cells with large nucleoli arranged in small sheets, within mucinous stroma. Sparse lymphocytic infiltrate was present, and no mitosis was detected [ Figure 3 ]. Immunohistochemical studies were performed using antibodies for glial fibrillary acidic protein (GFAP) (rabbit polyclonal antibody; DAKO; ready to use), CD34 (mouse monoclonal antibody; clone 9BEnd10; DAKO; ready to use), thyroid transcription factor (TTF)-1 (mouse monoclonal antibody; clone 8G7G3/1; DAKO; ready to use), and Ki-67 (mouse monoclonal antibody; clone MIB-1; DAKO; ready to use). Most tumor cells showed immunoreactivity for GFAP and CD34 [ Figure 4a and b]. In addition, almost all tumor cells appeared strongly positive for TTF-1 [ Figure 4c ]. The Ki-67 (MIB-1) proliferation-related labeling index was low, at 2.0% [ Figure 4d ]. With regard to the genetic profile, these tumor cells were immunonegative for R132H-mutated isocitrate dehydrogenase-1. Taking all these results into account, the final diagnosis was analysis of neuroimaging and immunohistochemical studies using CD34 and TTF-1 staining.
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DISCUSSION
Chordoid glioma of the third ventricle is a rare tumor with both glial and chordoid features. This tumor is currently recognized as a distinct glioma with grade II malignancy. [2, 3, 9, [12] [13] [14] 19, 20] In previous reports, chordoid glioma has been described as tending to occur in middle-aged and older adults (25-75 years). [8, 15] The clinical symptoms of this tumor are variable, according to tumor size and location. [3, 4, 9, 12, 18, 19] However, the epidemiology has not been clarified because of the low incidence of this tumor.
In terms of imaging characteristics, preoperative identification of this tumor with radiological examinations may be difficult. In general, MRI depicts chordoid glioma as isointense on T1WI, and iso-or slightly hyperintense on T2WI. Strong enhancement has been seen after administration of Gd. [3, 8, 19] In addition, another report described this tumor mass as generally showing a symmetrical distribution and causing vasogenic edema in compressed adjacent CNS structures, including the optic tracts, basal ganglia, and internal capsules. [6, 13] This perifocal edema in the optic tracts or basal ganglia on MRI (FLAIR) is extremely interesting and seems to be the key finding for accurate preoperative diagnosis of chordoid glioma. Therefore, we consider such recognition before surgery leads to safe, effective treatment of chordoid glioma.
In the 2016 revision of the WHO classification of CNS tumors, [13] the definition of chordoid glioma of the third ventricle is as follows: "A slow-growing, non-invasive glial tumor located in the third ventricle." Microscopically, chordoid glioma mainly consists of solid neoplasms composed of clusters and cords of epithelioid tumor cells within a variably mucinous stroma that typically contains a lymphoplasmacytic infiltrate. The nuclei are moderately sized, ovoid and relatively uniform, and mitotic figures are rare. [13] With regard to immunohistochemical characteristics, these tumor cells showed diffuse reactivity for GFAP. In addition, chordoid glioma was found to strongly express CD34, a transmembrane glycoprotein expressed on hematopoietic stem cells, vascular endothelia, and mesenchymal cells. [17] Usually, CD34 is negative in chordomas, meningiomas, and common forms of glioma such as diffuse astrocytomas, ependymomas, and oligodendrogliomas. On the other hand, CD34 is consistently positive in chordoid glioma, neurofibroma, solitary fibrous tumor, and meningeal hemangiopericytoma. [7] Moreover, chordoid gliomas were found to strongly express the nuclear transcription factor TTF-1, which is strongly expressed in the neurons and ependymal and subependymal cells of the third ventricle, as well as in hypothalamic astrocytes. [7, 10] Huo et al. reported that staining for both TTF-1 and CD34 is specifically expressed in chordoid glioma of the third ventricle, providing a useful marker for distinguishing such tumors from other suprasellar tumors and third ventricular tumor. [7] In our case, the tumor comprised clusters and cords of epithelioid cells that typically contained lymphoplasmacytic infiltration on morphological analysis. This structure was immunopositive for GFAP, and almost all tumor cells appeared strongly positive for CD34 and TTF-1. These findings are consistent with chordoid glioma in consideration of morphological studies and immunohistochemical analyses performed in accordance with the 2016 WHO classification. We, therefore, consider CD34 and TTF-1 as the most useful markers for accurate diagnosis of chordoid glioma of the third ventricle.
In terms of treatment, the best treatment strategy for this pathology remains controversial due to its rarity. [1, 7, 13] In general, surgical resection is the most important part of the treatment. The choice of surgical approach may be mainly due to the presence of objective variables such as ventricular extension, tumor laterality, as well as the surgeon's confidence. In previous reports comparing all conventional approaches, a surgical route using the translaminar terminalis corridor was associated with significantly decreased morbidity and mortality rates. [1, 11] However, surgical en bloc resection can be technically challenging considering the deep location of the tumor and its proximity to vital neurovascular structures and the hypothalamus. Surgeons have, therefore, attempted to balance maximal cytoreduction with complication avoidance. In addition, there are also reports of several other adjuvant therapy such as conventional radiotherapy, stereotactic radiosurgery, and intratumoral radiotherapy; however, no chemotherapy treatment is reported. [2] In the previous report, radiotherapy is often used as an adjuvant therapy in patients who undergo subtotal resection. [11] The knowledge of these promising tools for a combined treatment approach to these lesions could modify the surgical strategy. [11] On the other hand, recently, several reports identified that there was a recurrent D463H missense mutation in PRKCA in chordoid glioma of the third ventricle, which localizes in the kinase domain of the encoded protein kinase C alpha (PKCα). In addition, expression of mutant PRKCA in immortalized human astrocytes led to increased phospho-extracellular signal regulated kinase (ERK) and anchorage-independent growth that could be blocked by methyl ethyl ketone (MEK) inhibition. Therefore, the clarification of this genetic alteration has the potential to change the treatment paradigm for this uncommon tumor. [5, 16] In this case, we are convinced that taking into account the possibility of chordoid glioma before surgery resulted in safe, total removal without being surprised during surgery, in addition to excellent tumor control without neurological complications. Recognition of the detailed characteristics of chordoid glioma of the third ventricle is very important. Accumulation of further experience with this pathology and results from longer patient follow-up are required.
CONCLUSION
We suggest that chordoid glioma of the third ventricle should be included as a differential diagnosis for third ventricular tumors in patients with homogeneously enhancing lesions on MRI. In addition, this entity is difficult to diagnose using routine pathological analysis. Careful identification of signs from preoperative MRI and detailed evaluation of findings from morphological and immunohistochemical studies including CD34 and TTF-1 staining are important for accurate diagnosis and selection of appropriate treatment for chordoid glioma.
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